



IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

- *Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99)*
- *Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators*
- *Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world*

Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA March 8, 2021 – [IBA](#) (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, and [NorthStar Medical Radioisotopes](#), LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. The collaboration enables companies outside of the United States to access the Tc-99m Generation Systems (TCM Generation Systems) that utilize NorthStar's proprietary non-uranium based Mo-99 produced using IBA's accelerators and beamlines.

The collaboration builds on an existing contract under which IBA is providing NorthStar with up to eight Rhodotron® TT 300-HE electron beam accelerators. They will be used for the production of non-uranium based Mo-99, which enables NorthStar's FDA-approved and commercially available RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m in the United States. NorthStar's Accelerator Production facility expansion is nearing completion in Beloit, Wisconsin, with the first pair of IBA accelerators due to arrive from Belgium in early April 2021.

"Every year approximately 30 million patients benefit from diagnostic imaging studies using Tc-99m," **said Stephen Merrick, President and Chief Executive Officer of NorthStar**. "NorthStar is delighted to expand its collaboration with IBA, as we view them to be an ideal partner to grow the use of non-uranium based Mo-99 to support a sustainable and innovative future for nuclear medicine. Based on their commercial expertise and tailored approach, we believe IBA complements NorthStar's global vision of delivering innovative solutions that can address critical patient healthcare needs related to medical diagnosis. We are proud to lead the field of nuclear medicine as the only commercialized producer of Mo-99 in the United States, having provided more than two years of stable U.S. commercial production to date. We look forward to deepening our collaboration with IBA and are confident that this joint approach has the potential to make non-uranium Mo-99 the leading worldwide source of Tc-99m."

Olivier Legrain, Chief Executive Officer of IBA, commented, "We are pleased to enter into this expanded collaboration for TCM Generation Systems with NorthStar Medical Radioisotopes to enable more companies to access this vital healthcare diagnostic tool. IBA's Rhodotron® accelerators provide the most advanced accelerator technology in the world, and we look forward to working with NorthStar in applying



innovative solutions to enable reliable radioisotope supply on a global basis and exploring additional productive opportunities in the future.”

NorthStar’s Accelerator Production facility expansion in Beloit, Wisconsin, will ensure sustainable domestic Mo-99 supply for the United States through dual production and processing hubs for additional capacity and scheduling flexibility. Pending appropriate licensure and approval, the facility will augment current Mo-99 processing in Columbia, Missouri, conducted in partnership with the University of Missouri Research Reactor (MURR®).

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange Euronext (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About the RadioGenix® System (Technetium Tc 99m Generator)

The RadioGenix System is an innovative, high tech separation platform that is approved for processing non-uranium based molybdenum-99 (Mo-99) for the production of the important medical radioisotope, technetium-99m (Tc-99m). Prior to availability of RadioGenix technology, the U.S. supply chain for Mo-99 has been subject to frequent and sometimes severe interruptions which negatively impact patient healthcare. Approved by the U.S. Food and Drug Administration (FDA) in 2018, the RadioGenix System is the first and only on-site, automated isotope separation system of its kind for use with non-uranium based Mo-99, designed to help alleviate shortage situations and expand domestic supply. The RadioGenix System is not approved for use outside the United States.

About NorthStar Medical Radioisotopes, LLC (NorthStar)

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals. Its first FDA-approved diagnostic imaging product is technetium-99m (Tc-99m), which is used in 40,000 patient imaging studies per day in the United States as standard of care to assess extent and severity of heart disease and cancer. Tc-99m is generated by NorthStar’s novel RadioGenix® System (technetium Tc 99m generator) which uses U.S.-produced, non-uranium based molybdenum-99 (Mo-99) as its source material. The Company is executing a well-defined plan to consistently increase the scale of Mo-99 production and to continuously improve efficiencies to meet anticipated increased demand. Therapeutic radioisotopes are increasingly important cancer treatment options, and NorthStar is developing commercial-scale production technologies to meet high demand for their use in ongoing clinical trials by multiple pharmaceutical companies. In addition, the Company is advancing a portfolio of other radiopharmaceuticals for use in therapeutic and diagnostic applications. For more information, visit: www.northstarmm.com.



CONTACTS:

For IBA

Corporate and media enquiries:
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

Investor relations:
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
investorrelations@iba-group.com

For NorthStar Medical Radioisotopes, LLC

Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
lholt@northstarm.com

Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
pestrem@northstarm.com

Media:
Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com

#